Jason H Kurzer, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kurzer’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105341 · Current
Licensed to practise in California · since 2008 · expires 2027-12-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$39,947
Medicare paid this office $39,947 for 253 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 119 | $9,094 | $74 |
| Special stained specimen slides to examine tissue, each additional procedure | 49 | $6,786 | $24 |
| Pathology examination of tissue using a microscope, intermediate complexity | 85 | $4,256 | $33 |
| Bone marrow, smear interpretation | 77 | $3,316 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 54 | $3,065 | $55 |
See all 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 119 | $9,094 | $74 |
| Special stained specimen slides to examine tissue, each additional procedure | 49 | $6,786 | $24 |
| Pathology examination of tissue using a microscope, intermediate complexity | 85 | $4,256 | $33 |
| Bone marrow, smear interpretation | 77 | $3,316 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 54 | $3,065 | $55 |
| Special stained specimen slides to examine tissue, initial procedure | 68 | $2,138 | $31 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 25 | $1,955 | $75 |
| Microscopic genetic analysis of tumor, manual | 30 | $1,787 | $37 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 22 | $1,745 | $79 |
| Genetic sequencing localization, initial procedure | 42 | $1,519 | $36 |
| Genetic sequencing localization, each additional procedure | 37 | $1,246 | $30 |
| Preparation of tissue for examination by removing any calcium present | 76 | $842 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 32 | $446 | $11 |
| Cell examination of specimen, concentration technique | 15 | $283 | $17 |
Who their Medicare patients are
253 Original Medicare patients in 2024. Average age 73 · Under 65 9% · 85 and older 13% · Women 44% · Also on Medicaid 27% · Health risk score 2.22. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Chronic kidney disease 34% · Coronary heart disease 32% · Diabetes 31% · Heart failure 25% · Cancer 21% · Depression 21% · Atrial fibrillation 20% · COPD 19% · Dementia 12% · Stroke 11%.
The office billed $424,683, Medicare allowed $51,046 and paid $39,947; for 1,098 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 253 | 1,098 | 73 | 2.22 | $424,683 | $39,947 |
| 2023 | 174 | 739 | 73 | 2.16 | $248,605 | $27,980 |
| 2022 | 199 | 770 | 74 | 2.26 | $228,592 | $29,725 |
| 2021 | 181 | 744 | 72 | 1.79 | $202,733 | $29,651 |
| 2020 | 209 | 906 | 72 | 2.49 | $234,843 | $35,344 |
| 2019 | 227 | 1,052 | 72 | 2.44 | $273,752 | $40,704 |
| 2018 | 187 | 628 | 72 | 2.35 | $169,513 | $26,673 |
| 2017 | 262 | 795 | 71 | 2.23 | $217,517 | $34,799 |
| 2016 | 115 | 262 | 72 | 1.82 | $80,951 | $14,375 |
| 2014 | 77 | 295 | 69 | 2.50 | $82,235 | $11,210 |
| 2013 | 126 | 389 | 69 | 2.39 | $102,713 | $14,838 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 71 | $5,535 | $76 |
| Special stained specimen slides to examine tissue, each additional procedure | 37 | $4,515 | $26 |
| Bone marrow, smear interpretation | 69 | $3,059 | $44 |
| Pathology examination of tissue using a microscope, intermediate complexity | 70 | $3,059 | $34 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 43 | $2,608 | $58 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 21 | $1,795 | $82 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 18 | $1,387 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 39 | $1,333 | $33 |
| Microscopic genetic analysis of tumor, manual | 21 | $1,323 | $39 |
| Genetic sequencing localization, initial procedure | 20 | $804 | $40 |
| Preparation of tissue for examination by removing any calcium present | 69 | $794 | $11 |
| Genetic sequencing localization, each additional procedure | 16 | $540 | $32 |
| Cell examination of specimen, concentration technique | 19 | $439 | $21 |
| Special stained specimen slides to examine tissue including interpretation and report | 31 | $422 | $11 |
2022: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 87 | $6,915 | $76 |
| Special stained specimen slides to examine tissue, each additional procedure | 37 | $4,812 | $26 |
| Bone marrow, smear interpretation | 65 | $2,999 | $45 |
| Pathology examination of tissue using a microscope, intermediate complexity | 69 | $2,719 | $35 |
| Microscopic genetic analysis of tumor, manual | 29 | $1,780 | $39 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 23 | $1,710 | $74 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 30 | $1,621 | $51 |
| Special stained specimen slides to examine tissue, initial procedure | 43 | $1,461 | $32 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 17 | $1,381 | $81 |
| Genetic sequencing localization, initial procedure | 24 | $978 | $41 |
| Preparation of tissue for examination by removing any calcium present | 64 | $760 | $12 |
| Genetic sequencing localization, each additional procedure | 18 | $610 | $32 |
| Cell examination of specimen, concentration technique | 22 | $461 | $21 |
| Special stained specimen slides to examine tissue including interpretation and report | 22 | $325 | $11 |
2021: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 72 | $5,829 | $79 |
| Special stained specimen slides to examine tissue, each additional procedure | 44 | $5,382 | $27 |
| Microscopic genetic analysis of tumor, manual | 31 | $2,203 | $40 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 26 | $2,147 | $83 |
| Bone marrow, smear interpretation | 43 | $2,071 | $43 |
| Pathology examination of tissue using a microscope, intermediate complexity | 45 | $1,862 | $35 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 24 | $1,853 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 50 | $1,740 | $33 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 27 | $1,656 | $57 |
| Genetic sequencing localization, initial procedure | 28 | $1,204 | $42 |
| Genetic sequencing localization, each additional procedure | 17 | $662 | $33 |
| Preparation of tissue for examination by removing any calcium present | 43 | $532 | $12 |
| Cell examination of specimen, concentration technique | 17 | $388 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 20 | $309 | $11 |
2020: 14 services
| Special stained specimen slides to examine tissue, each additional procedure | 59 | $7,219 | $28 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 66 | $5,204 | $78 |
| Microscopic genetic analysis of tumor, manual | 39 | $2,643 | $41 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 32 | $2,641 | $83 |
| Bone marrow, smear interpretation | 55 | $2,637 | $47 |
| Special stained specimen slides to examine tissue, initial procedure | 68 | $2,462 | $35 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 32 | $2,306 | $56 |
| Pathology examination of tissue using a microscope, intermediate complexity | 60 | $2,256 | $36 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 21 | $1,757 | $80 |
| Genetic sequencing localization, initial procedure | 38 | $1,629 | $43 |
| Genetic sequencing localization, each additional procedure | 24 | $948 | $34 |
| Cell examination of specimen, concentration technique | 40 | $918 | $22 |
| Preparation of tissue for examination by removing any calcium present | 58 | $702 | $12 |
| Special stained specimen slides to examine tissue including interpretation and report | 20 | $351 | $12 |
2019: 15 services
| Special stained specimen slides to examine tissue, each additional procedure | 59 | $7,791 | $27 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 80 | $6,398 | $77 |
| Bone marrow, smear interpretation | 77 | $3,470 | $45 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 39 | $3,084 | $79 |
| Pathology examination of tissue using a microscope, intermediate complexity | 78 | $3,024 | $36 |
| Special stained specimen slides to examine tissue, initial procedure | 69 | $2,797 | $34 |
| Microscopic genetic analysis of tumor, manual | 41 | $2,325 | $40 |
| Genetic sequencing localization, initial procedure | 46 | $2,108 | $41 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 23 | $1,996 | $83 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 24 | $1,621 | $60 |
| Pathology examination of tissue using a microscope, moderately high complexity | 11 | $1,362 | $80 |
| Genetic sequencing localization, each additional procedure | 30 | $1,301 | $33 |
| Preparation of tissue for examination by removing any calcium present | 73 | $879 | $12 |
| Special stained specimen slides to examine tissue including interpretation and report | 33 | $609 | $11 |
| Cell examination of specimen, concentration technique | 19 | $431 | $22 |
2018: 13 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 71 | $5,465 | $77 |
| Special stained specimen slides to examine tissue, each additional procedure | 29 | $3,287 | $27 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 40 | $3,064 | $77 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 26 | $2,754 | $60 |
| Bone marrow, smear interpretation | 33 | $1,613 | $45 |
| Pathology examination of tissue using a microscope, intermediate complexity | 40 | $1,554 | $35 |
| Microscopic genetic analysis of tumor, manual | 17 | $1,492 | $43 |
| Special stained specimen slides to examine tissue, initial procedure | 35 | $1,252 | $33 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 19 | $800 | $42 |
| Genetic sequencing localization, initial procedure | 19 | $756 | $40 |
| Preparation of tissue for examination by removing any calcium present | 33 | $457 | $12 |
| Cell examination of specimen, concentration technique | 21 | $453 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $383 | $11 |
2017: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 98 | $8,262 | $83 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 56 | $4,314 | $77 |
| Bone marrow, smear interpretation | 74 | $3,451 | $45 |
| Pathology examination of tissue using a microscope, intermediate complexity | 77 | $3,174 | $36 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 29 | $2,771 | $69 |
| Special stained specimen slides to examine tissue, each additional procedure | 32 | $2,657 | $27 |
| Microscopic genetic analysis of tumor, manual | 20 | $1,667 | $52 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 25 | $1,516 | $56 |
| Special stained specimen slides to examine tissue, initial procedure | 41 | $1,486 | $34 |
| Preparation of tissue for examination by removing any calcium present | 71 | $877 | $12 |
| Cell examination of specimen, concentration technique | 36 | $819 | $21 |
| Genetic sequencing localization, initial procedure | 18 | $797 | $42 |
| Special stained specimen slides to examine tissue including interpretation and report | 36 | $641 | $11 |
| Genetic sequencing localization, each additional procedure | 11 | $429 | $33 |
2016: 7 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 58 | $6,261 | $101 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 25 | $2,510 | $81 |
| Bone marrow, smear interpretation | 28 | $1,275 | $44 |
| Pathology examination of tissue using a microscope, intermediate complexity | 20 | $719 | $36 |
| Blood smear interpretation by physician with written report | 13 | $300 | $23 |
| Preparation of tissue for examination by removing any calcium present | 20 | $276 | $12 |
| Cell examination of specimen, concentration technique | 11 | $258 | $22 |
2014: 7 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 38 | $3,872 | $97 |
| Bone marrow, smear interpretation | 50 | $2,266 | $42 |
| Pathology examination of tissue using a microscope, intermediate complexity | 48 | $1,835 | $35 |
| Preparation of tissue for examination by removing any calcium present | 48 | $582 | $11 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 11 | $303 | $28 |
| Cell examination of specimen, concentration technique | 13 | $290 | $19 |
| Special stained specimen slides to examine tissue including interpretation and report | 13 | $195 | $11 |
2013: 7 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 52 | $5,081 | $94 |
| Bone marrow, smear interpretation | 62 | $2,791 | $42 |
| Pathology examination of tissue using a microscope, intermediate complexity | 58 | $2,056 | $33 |
| Cell examination of specimen, concentration technique | 42 | $781 | $17 |
| Preparation of tissue for examination by removing any calcium present | 58 | $684 | $11 |
| Blood smear interpretation by physician with written report | 15 | $345 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 18 | $308 | $11 |
Medicaid work
$4,614 in 2024
Medicaid paid $4,614 for 202 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Bone marrow, smear interpretation | 41 | $1,412 |
| TISSUE EXAM BY PATHOLOGIST | 35 | $982 |
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 30 | $826 |
| Blood smear, peripheral, interpretation by physician with written report | 56 | $785 |
| Flow cytometry, interpretation; 16 or more markers | 12 | $489 |
| DECALCIFICATION PROCEDURE | 28 | $120 |
| 2024 | 202 | 6 | 27 | $4,614 |
| 2023 | 86 | 6 | 19 | $3,455 |
| 2022 | 35 | 1 | 20 | $686 |
| 2021 | 16 | 1 | 14 | $290 |
| 2020 | 86 | 1 | 20 | $2,036 |
| 2019 | 151 | 4 | 26 | $3,760 |
| 2018 | 95 | 4 | 24 | $2,668 |
See the largest Medicaid services in earlier years
2023
| Flow cytometry, interpretation; 16 or more markers | 12 | $1,052 |
| Bone marrow, smear interpretation | 15 | $878 |
| TISSUE EXAM BY PATHOLOGIST | 13 | $772 |
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 14 | $317 |
| Blood smear, peripheral, interpretation by physician with written report | 19 | $300 |
| DECALCIFICATION PROCEDURE | 13 | $136 |
2022
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 35 | $686 |
2021
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 16 | $290 |
2020
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 86 | $2,036 |
2019
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 64 | $1,608 |
| Bone marrow, smear interpretation | 51 | $1,563 |
| TISSUE EXAM BY PATHOLOGIST | 18 | $494 |
| DECALCIFICATION PROCEDURE | 18 | $95 |
2018
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 56 | $1,509 |
| TISSUE EXAM BY PATHOLOGIST | 12 | $551 |
| Bone marrow, smear interpretation | 15 | $540 |
| DECALCIFICATION PROCEDURE | 12 | $69 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1649468802
- Licence
- CA A105341California A105341: Current · expires 2027-12-31
- Trained
- University of Michigan Medical School, 2007
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZC0006X (207ZC0006X); Federal specialty code 207ZH0000X (207ZH0000X); Federal specialty code 207ZP0101X (207ZP0101X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-10-11
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.